10,677 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Acquired by Weiss Asset Management LP

Weiss Asset Management LP acquired a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLSFree Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,677 shares of the company’s stock, valued at approximately $639,000.

A number of other hedge funds have also recently added to or reduced their stakes in APLS. Covestor Ltd increased its holdings in Apellis Pharmaceuticals by 564.2% in the third quarter. Covestor Ltd now owns 797 shares of the company’s stock worth $30,000 after buying an additional 677 shares during the last quarter. Quantbot Technologies LP increased its holdings in Apellis Pharmaceuticals by 280.5% in the third quarter. Quantbot Technologies LP now owns 4,798 shares of the company’s stock worth $183,000 after buying an additional 3,537 shares during the last quarter. HC Advisors LLC acquired a new position in Apellis Pharmaceuticals in the fourth quarter worth approximately $210,000. Whittier Trust Co. acquired a new position in Apellis Pharmaceuticals in the fourth quarter worth approximately $221,000. Finally, Prime Capital Investment Advisors LLC acquired a new position in Apellis Pharmaceuticals during the fourth quarter valued at approximately $229,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Insider Transactions at Apellis Pharmaceuticals

In other news, CEO Cedric Francois sold 250,000 shares of Apellis Pharmaceuticals stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $64.11, for a total transaction of $16,027,500.00. Following the transaction, the chief executive officer now owns 313,662 shares in the company, valued at approximately $20,108,870.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 250,000 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $64.11, for a total value of $16,027,500.00. Following the sale, the chief executive officer now owns 313,662 shares in the company, valued at approximately $20,108,870.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director A. Sinclair Dunlop sold 18,681 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $57.18, for a total value of $1,068,179.58. Following the completion of the sale, the director now owns 173,998 shares in the company, valued at approximately $9,949,205.64. The disclosure for this sale can be found here. In the last ninety days, insiders sold 448,012 shares of company stock worth $26,015,139. 6.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have commented on APLS shares. Wedbush lowered their price target on Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. HC Wainwright restated a “buy” rating and issued a $92.00 price objective on shares of Apellis Pharmaceuticals in a research note on Tuesday. UBS Group lowered their price objective on shares of Apellis Pharmaceuticals from $89.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Mizuho lowered their price objective on shares of Apellis Pharmaceuticals from $60.00 to $52.00 and set a “neutral” rating on the stock in a research note on Monday, April 29th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $76.27.

Get Our Latest Stock Report on APLS

Apellis Pharmaceuticals Price Performance

Shares of Apellis Pharmaceuticals stock traded up $0.62 during trading on Wednesday, reaching $41.18. The company’s stock had a trading volume of 726,282 shares, compared to its average volume of 1,528,846. The stock has a 50-day moving average price of $49.18 and a two-hundred day moving average price of $56.92. The company has a current ratio of 3.77, a quick ratio of 3.02 and a debt-to-equity ratio of 0.35. Apellis Pharmaceuticals, Inc. has a one year low of $19.83 and a one year high of $94.75. The stock has a market capitalization of $5.00 billion, a P/E ratio of -11.67 and a beta of 0.97.

Apellis Pharmaceuticals (NASDAQ:APLSGet Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.54) EPS for the quarter, hitting analysts’ consensus estimates of ($0.54). The firm had revenue of $172.33 million during the quarter, compared to analyst estimates of $163.37 million. Apellis Pharmaceuticals had a negative return on equity of 160.77% and a negative net margin of 79.67%. The company’s revenue was up 284.3% on a year-over-year basis. During the same period last year, the company earned ($1.56) earnings per share. As a group, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.12 EPS for the current fiscal year.

Apellis Pharmaceuticals Company Profile

(Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Featured Stories

Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. (NASDAQ:APLSFree Report).

Institutional Ownership by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.